It's not a pill. It's called WATCHMAN
Answer a few short questions to see if you may be a candidate
The WATCHMAN Difference
WATCHMAN offers an alternative to the lifelong use of warfarin for people with atrial fibrillation not caused by a heart valve problem (also known as non-valvular AFib).
This permanent heart implant effectively reduces the risk of stroke—without the risk of bleeding that can come with the long-term use of warfarin (the most common blood thinner).1,2 What’s more, WATCHMAN can eliminate the regular blood tests and food-and-drink restrictions that come with warfarin. (Warfarin is also known as Coumadin®.)
In a clinical trial, 9 out of 10 people were able to stop taking warfarin just 45 days after the WATCHMAN procedure.1
Meet Dr. Adam Rosenbluth
Dr. Rosenbluth is a clinical cardiologist who’s been in practice for over 16 years. Dr. Rosenbluth referred appropriate patients for the WATCHMAN Implant during the clinical trials. And he continues to counsel patients about this life-changing procedure today. In the video below, he explains how WATCHMAN works and describes the WATCHMAN procedure.
How WATCHMAN Works
To understand how WATCHMAN works, it helps to know more about the connection between atrial fibrillation and stroke.
Atrial fibrillation, or AFib, affects your heart’s ability to pump blood normally. This can cause blood to pool in an area of the heart called the left atrial appendage, or LAA. There, blood cells can stick together and form a clot. When a blood clot escapes from the LAA and travels to another part of the body, it can cut off the blood supply to the brain, causing a stroke.3,4
In people with AFib not caused by a heart valve problem, more than 90% of stroke-causing clots that come from the heart are formed in the LAA.3 That’s why closing off this part of the heart is an effective way to reduce stroke risk.
The WATCHMAN Implant fits right into your LAA. It’s designed to permanently close it off and keep those blood clots from escaping. WATCHMAN is about the size of a quarter and made from very light and compact materials commonly used in many other medical implants.
The WATCHMAN Procedure
WATCHMAN is implanted into your heart in a one-time procedure. It’s a permanent device that doesn’t have to be replaced and can’t be seen outside the body.
To implant WATCHMAN, your doctor makes a small cut in your upper leg and inserts a narrow tube, as done in a standard stent procedure. Your doctor then guides WATCHMAN into the left atrial appendage (LAA) of your heart. The procedure is done under general anesthesia and takes about an hour. Patients commonly stay in the hospital overnight and leave the next day.
Due to the risk of having a medical procedure, patients should not be considered for WATCHMAN if they are doing well and expect to continue doing well on blood thinners.
Questions about WATCHMAN?
WATCHMAN Educational Specialists are trained professionals with healthcare experience. They're here to help answer your questions.
Monday to Friday, 8AM to 5PM Central Time
After the Procedure
Following the WATCHMAN procedure, you’ll take warfarin (a common blood thinner) for 45 days or until your LAA is permanently closed off. During this time, heart tissue will grow over the implant to form a barrier against blood clots. Your doctor will monitor this process by taking pictures of your heart to see when you can stop taking warfarin.
Your doctor will then prescribe a medicine called clopidogrel (also known as Plavix®) and aspirin for you to take for 6 months. After that, you’ll continue to take aspirin on an ongoing basis. A very small number of patients may need to keep taking blood thinners long term.
In a clinical trial:
- 92% of patients were able to stop taking warfarin just 45 days after the procedure1
- 99% of patients were able to stop taking warfarin within 1 year after the procedure1
Studies of WATCHMAN
WATCHMAN is the only device of its kind approved by the U.S. Food and Drug Administration (FDA) for reducing the risk of stroke in people with atrial fibrillation not caused by a heart valve problem.
More than 100,000 WATCHMAN procedures have been performed worldwide. With almost 20 years of clinical trial and real world experience - including 10 clinical trials - WATCHMAN has a proven safety record.
In a post FDA approval analysis, major complications occurred in 1.5% of cases from time of implant to 7 days post-implantation or hospital discharge, which is a similar rate to an ablation procedure.2
As with any medical procedure, there are risks involved with WATCHMAN. See the Important Safety Information below for a list of possible complications, and ask your cardiologist about the risks and benefits of WATCHMAN.
WATCHMAN is for people with atrial fibrillation not caused by a heart valve problem who need an alternative to warfarin. This website is intended to provide patients and caregivers with some information about the WATCHMAN Implant. It may help prepare you for talking to your doctor about your options for reducing stroke risk.
Important Safety Information
The WATCHMAN Device is a permanent implant designed to close the left atrial appendage in the heart in an effort to reduce the risk of stroke.
With all medical procedures there are risks associated with the implant procedure and the use of the device. The risks include but are not limited to accidental heart puncture, air embolism, allergic reaction, anemia, anesthesia risks, arrhythmias, AV (Arteriovenous) fistula, bleeding or throat pain from the TEE (Trans Esophageal Echo) probe, blood clot or air bubbles in the lungs or other organs, bruising at the catheter insertion site, clot formation on the WATCHMAN™ Closure Device, cranial bleed, excessive bleeding, gastrointestinal bleeding, groin puncture bleed, hypotension, infection/pneumonia, pneumothorax, pulmonary edema, pulmonary vein obstruction, renal failure, stroke, thrombosis and transient ischemic attack. In rare cases death can occur.
Be sure to talk with your doctor so that you thoroughly understand all of the risks and benefits associated with the implantation of the WATCHMAN Device.
- Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12.
- Ellenbogen KA, et al. Heart Rhythm. 2019; 16(5): S310.
- Price MJ, Reddy VY, Valderrábano M, et al. Bleeding outcomes after left atrial appendage closure compared with long-term warfarin. JACC Cardiovasc Interv. 2015;8(15):1925-1932.
- Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-759.
- National Stroke Association. Making the Afib-Stroke Connection. https://www.stroke.org/sites/default/files/resources/Afib-Connection%20for%20hcp.pdf. Published 2012. Accessed September 1, 2016.
- Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65(24):2614-2623.